Log In
Print
BCIQ
Print
Print this Print this
 

tesevatinib (XL647) (formerly KD019)

  Manage Alerts
Collapse Summary General Information
Company Symphony Evolution Inc.
DescriptionTyrosine kinase inhibitor (TKI) that targets EGFR, VEGF receptor 2 (VEGFR-2; KDR/Flk-1), HER2 and Src
Molecular Target Vascular endothelial growth factor (VEGF) receptor 2 (VEGFR-2) (KDR/Flk-1) ; Epidermal growth factor receptor 2 (HER2) (EGFR2) (ErbB2) (neu)
Mechanism of ActionKinase inhibitor
Therapeutic Modality 

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today